Global Financial Private Capital LLC trimmed its position in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 54.8% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,753 shares of the biopharmaceutical company’s stock after selling 2,126 shares during the period. Global Financial Private Capital LLC’s holdings in Alexion Pharmaceuticals were worth $244,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently added to or reduced their stakes in the company. First Hawaiian Bank acquired a new stake in shares of Alexion Pharmaceuticals in the third quarter worth approximately $102,000. Advisory Services Network LLC boosted its stake in shares of Alexion Pharmaceuticals by 145.3% in the second quarter. Advisory Services Network LLC now owns 883 shares of the biopharmaceutical company’s stock worth $121,000 after acquiring an additional 523 shares during the last quarter. Checchi Capital Advisers LLC acquired a new stake in shares of Alexion Pharmaceuticals in the third quarter worth approximately $204,000. K.J. Harrison & Partners Inc acquired a new stake in shares of Alexion Pharmaceuticals in the third quarter worth approximately $209,000. Finally, Bbva Compass Bancshares Inc. acquired a new stake in shares of Alexion Pharmaceuticals in the third quarter worth approximately $218,000. Institutional investors own 93.33% of the company’s stock.

A number of brokerages have recently issued reports on ALXN. BidaskClub raised Alexion Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, September 29th. Barclays boosted their price objective on Alexion Pharmaceuticals to $175.00 and gave the stock an “overweight” rating in a research note on Friday, September 28th. ValuEngine lowered Alexion Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, October 4th. Zacks Investment Research raised Alexion Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, October 5th. Finally, Credit Suisse Group set a $156.00 target price on Alexion Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, September 25th. Three analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $161.50.

In related news, EVP Indrani Lall Franchini sold 2,605 shares of the business’s stock in a transaction on Wednesday, November 28th. The stock was sold at an average price of $118.13, for a total transaction of $307,728.65. Following the completion of the transaction, the executive vice president now directly owns 29,304 shares of the company’s stock, valued at approximately $3,461,681.52. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 4.35% of the company’s stock.

Shares of ALXN stock traded down $5.44 on Friday, hitting $115.60. The stock had a trading volume of 1,229,654 shares, compared to its average volume of 1,105,094. The company has a current ratio of 3.16, a quick ratio of 2.74 and a debt-to-equity ratio of 0.32. The company has a market capitalization of $27.00 billion, a PE ratio of 22.40, a P/E/G ratio of 1.04 and a beta of 1.02. Alexion Pharmaceuticals, Inc. has a 1 year low of $102.10 and a 1 year high of $140.77.

Alexion Pharmaceuticals (NASDAQ:ALXN) last released its earnings results on Wednesday, October 24th. The biopharmaceutical company reported $2.02 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.74 by $0.28. Alexion Pharmaceuticals had a return on equity of 16.60% and a net margin of 3.90%. The firm had revenue of $1.03 billion during the quarter, compared to analysts’ expectations of $1.02 billion. During the same period in the previous year, the firm posted $1.44 EPS. Alexion Pharmaceuticals’s revenue for the quarter was up 19.5% on a year-over-year basis. Research analysts predict that Alexion Pharmaceuticals, Inc. will post 6.82 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This report was originally reported by Marea Informative and is owned by of Marea Informative. If you are accessing this report on another site, it was stolen and republished in violation of United States & international copyright & trademark law. The original version of this report can be viewed at https://www.mareainformativa.com/news/2018/12/08/global-financial-private-capital-llc-reduces-stake-in-alexion-pharmaceuticals-inc-alxn-updated-updated-updated.html.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; atypical hemolytic uremic syndrome (aHUS), a genetic disease; and generalized myasthenia gravis, a debilitating, complement-mediated neuromuscular disease.

Further Reading: How Do I Invest in Dividend Stocks

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.